Related references
Note: Only part of the references are listed.The fragility of randomized controlled trials in intracranial hemorrhage
Yanfei Shen et al.
NEUROSURGICAL REVIEW (2019)
Comment on Post-hoc Power Using Observed Estimate of Effect Size is too Noisy to be Useful''
Andrew Gelman
ANNALS OF SURGERY (2019)
Assessing quality of randomized trials supporting guidelines for laparoscopic and endoscopic surgery
Aaron Bowers et al.
JOURNAL OF SURGICAL RESEARCH (2018)
Evaluation of Lowering the P Value Threshold for Statistical Significance From .05 to .005 in Previously Published Randomized Clinical Trials in Major Medical Journals
Cole Wayant et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
The Fragility of Statistically Significant Findings From Randomized Trials in Sports Surgery: A Systematic Survey
Moin Khan et al.
AMERICAN JOURNAL OF SPORTS MEDICINE (2017)
The fragility of significant results underscores the need of larger randomized controlled trials in nephrology
Lani R. Shochet et al.
KIDNEY INTERNATIONAL (2017)
The Fragility Index in a Cohort of Pediatric Randomized Controlled Trials
Travis J. Matics et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Does Sample Size Matter When Interpreting the Fragility Index?
Wael Ahmed et al.
CRITICAL CARE MEDICINE (2016)
The Fragility Index in Multicenter Randomized Controlled Critical Care Trials
Elliott E. Ridgeon et al.
CRITICAL CARE MEDICINE (2016)
The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey
Nathan Evaniew et al.
SPINE JOURNAL (2015)
The Extent and Consequences of P-Hacking in Science
Megan L. Head et al.
PLOS BIOLOGY (2015)
The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index
Michael Walsh et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2014)
Power failure: why small sample size undermines the reliability of neuroscience
Katherine S. Button et al.
NATURE REVIEWS NEUROSCIENCE (2013)
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study
Torsak Bunupuradah et al.
ANTIVIRAL THERAPY (2012)
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Contemporary costs of HIV healthcare in the HAART era
Kelly A. Gebo et al.
AIDS (2010)
The lifetime cost of current human immunodeficiency virus care in the United States
Bruce R. Schackman et al.
MEDICAL CARE (2006)
Share Paper
